Inside the 2026 Biotech Landscape: Innovation, Investment and Global Momentum

https://is1-ssl.mzstatic.com/image/thumb/Podcasts116/v4/e0/16/a7/e016a72a-3255-8e4c-804e-6855e685a274/mza_18057399343301114994.jpg/600x600bb.jpg

BioSpace

188 episodes

1 day ago

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Life Sciences

Science

RSS

All content for BioSpace is the property of BioSpace and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Life Sciences

Science

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/39510587/39510587-1765898304934-85502caa0e5d1.jpg

Inside the 2026 Biotech Landscape: Innovation, Investment and Global Momentum

BioSpace

28 minutes 37 seconds

2 weeks ago

Inside the 2026 Biotech Landscape: Innovation, Investment and Global Momentum

In this episode of Denatured, Jennifer Smith-Parker speaks to Kenneth Galbraith, CEO at Zymeworks and Josh Smiley, president and COO at Zai Lab, about how renewed confidence is driving biotech entering 2026.

As we look towards conversations that will shape this year's J.P. Morgan Healthcare Conference, the biotech industry is fueled by improving market sentiments, visible at recent meetings like Jeffries in London, and reinforced by a wave of partnerships, strategic acquisitions and Chinese collaboration that is recalibrating investor expectations.

Host

Jennifer Smith-Parker, Director of Insights, BioSpace

Guests

Kenneth Galbraith, CEO, Zymeworks

Josh Smiley, President and Chief Operating Officer, Zai Lab

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.